Zovanta D 30mg/40mg Capsule is a combination medication containing Domperidone 30mg and Pantoprazole 40mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The combination provides synergistic effects by addressing both impaired motility and excessive acid production. Zovanta D is typically administered orally once daily before meals, with dosage and duration tailored to the patient's clinical condition and response. It is contraindicated in patients with hypersensitivity to either component, and caution is advised in individuals with hepatic impairment or prolactin-secreting pituitary tumors. Common adverse effects may include headache, dry mouth, abdominal discomfort, and, rarely, extrapyramidal symptoms. Regular monitoring and adherence to prescribed dosing are essential to optimize therapeutic outcomes and minimize potential risks. Zovanta D offers an effective therapeutic option for patients requiring combined prokinetic and acid-suppressive treatment.